- Home
- RLX vs CRNX Comparison
RLX vs CRNX Comparison
Compare RLX & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- CRNX
- Stock Information
- Founded
- RLX 2018
- CRNX 2008
- Country
- RLX China
- CRNX United States
- Employees
- RLX N/A
- CRNX N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- CRNX Health Care
- Exchange
- RLX Nasdaq
- CRNX Nasdaq
- Market Cap
- RLX 2.8B
- CRNX 2.8B
- IPO Year
- RLX 2021
- CRNX 2018
- Fundamental
- Price
- RLX $2.60
- CRNX $41.51
- Analyst Decision
- RLX Hold
- CRNX Buy
- Analyst Count
- RLX 1
- CRNX 12
- Target Price
- RLX $2.25
- CRNX $74.45
- AVG Volume (30 Days)
- RLX 3.8M
- CRNX 2.0M
- Earning Date
- RLX 11-14-2025
- CRNX 11-11-2025
- Dividend Yield
- RLX 0.38%
- CRNX N/A
- EPS Growth
- RLX 12.15
- CRNX N/A
- EPS
- RLX 0.08
- CRNX N/A
- Revenue
- RLX $407,348,055.00
- CRNX $1,392,000.00
- Revenue This Year
- RLX $59.70
- CRNX $469.59
- Revenue Next Year
- RLX $27.15
- CRNX $705.27
- P/E Ratio
- RLX $33.83
- CRNX N/A
- Revenue Growth
- RLX 55.36
- CRNX 0.51
- 52 Week Low
- RLX $1.57
- CRNX $24.10
- 52 Week High
- RLX $2.84
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- RLX 58.71
- CRNX 64.29
- Support Level
- RLX $2.45
- CRNX $40.80
- Resistance Level
- RLX $2.68
- CRNX $47.41
- Average True Range (ATR)
- RLX 0.07
- CRNX 2.15
- MACD
- RLX -0.01
- CRNX 0.61
- Stochastic Oscillator
- RLX 63.04
- CRNX 58.26
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.